Merck & Co., Inc. (NYSE:MRK) Shares Sold by BlackRock Inc.

BlackRock Inc. lowered its position in Merck & Co., Inc. (NYSE:MRK) by 3.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 187,155,493 shares of the company’s stock after selling 6,772,917 shares during the quarter. BlackRock Inc. owned about 7.39% of Merck & Co., Inc. worth $14,555,084,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Cowen Prime Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $31,000. PARK CIRCLE Co increased its stake in shares of Merck & Co., Inc. by 100.0% during the second quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock valued at $31,000 after acquiring an additional 200 shares during the period. AlphaMark Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $39,000. Lake Point Wealth Management acquired a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $40,000. Finally, ShoreHaven Wealth Partners LLC increased its stake in shares of Merck & Co., Inc. by 55.5% during the first quarter. ShoreHaven Wealth Partners LLC now owns 619 shares of the company’s stock valued at $48,000 after acquiring an additional 221 shares during the period. Institutional investors own 71.83% of the company’s stock.

Merck & Co., Inc. stock traded up $0.76 during midday trading on Monday, reaching $72.44. The stock had a trading volume of 461,053 shares, compared to its average volume of 11,373,343. The firm’s fifty day simple moving average is $76.32 and its two-hundred day simple moving average is $76.57. Merck & Co., Inc. has a twelve month low of $70.75 and a twelve month high of $85.60. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06. The firm has a market cap of $183.37 billion, a price-to-earnings ratio of 32.73, a PEG ratio of 2.16 and a beta of 0.41.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Wednesday, July 28th. The company reported $1.31 EPS for the quarter, hitting analysts’ consensus estimates of $1.31. Merck & Co., Inc. had a net margin of 11.48% and a return on equity of 50.93%. The firm had revenue of $11.40 billion during the quarter, compared to analyst estimates of $11.21 billion. During the same quarter last year, the business posted $1.37 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 5.51 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be paid a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date is Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is 43.77%.

MRK has been the topic of a number of research analyst reports. Truist initiated coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 27th. They set a “buy” rating and a $92.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 9th. Morgan Stanley cut shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $90.00 to $85.00 in a report on Tuesday, September 7th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price for the company in a report on Tuesday, August 24th. Finally, SVB Leerink raised their target price on shares of Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $91.09.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More: Analyst Ratings Trading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.